145 related articles for article (PubMed ID: 29441509)
1. NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas.
Haapasalo J; Nordfors K; Granberg KJ; Kivioja T; Nykter M; Haapasalo H; Soini Y
Histol Histopathol; 2018 Aug; 33(8):791-801. PubMed ID: 29441509
[TBL] [Abstract][Full Text] [Related]
2. Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer.
Merikallio H; Pääkkö P; Kinnula VL; Harju T; Soini Y
Hum Pathol; 2012 Apr; 43(4):577-84. PubMed ID: 21943684
[TBL] [Abstract][Full Text] [Related]
3. Nuclear Nrf2 expression is related to a poor survival in pancreatic adenocarcinoma.
Soini Y; Eskelinen M; Juvonen P; Kärjä V; Haapasaari KM; Saarela A; Karihtala P
Pathol Res Pract; 2014 Jan; 210(1):35-9. PubMed ID: 24189098
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
[TBL] [Abstract][Full Text] [Related]
5. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
6. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
7. Nuclear karyopherin a2: a novel biomarker for infiltrative astrocytomas.
Gousias K; Becker AJ; Simon M; Niehusmann P
J Neurooncol; 2012 Sep; 109(3):545-53. PubMed ID: 22772608
[TBL] [Abstract][Full Text] [Related]
8. Hsp27 and its expression pattern in diffusely infiltrating astrocytomas.
Mäkelä KS; Haapasalo JA; Ilvesaro JM; Parkkila S; Paavonen T; Haapasalo HK
Histol Histopathol; 2014 Sep; 29(9):1161-8. PubMed ID: 24599602
[TBL] [Abstract][Full Text] [Related]
9. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
[TBL] [Abstract][Full Text] [Related]
10. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
[TBL] [Abstract][Full Text] [Related]
11. In vivo Metabolic Profiles as Determined by
Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
[TBL] [Abstract][Full Text] [Related]
12. High CHI3L1 expression is associated with glioma patient survival.
Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P
Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms and protein expression of NRF2 and Sulfiredoxin predict survival outcomes in breast cancer.
Hartikainen JM; Tengström M; Kosma VM; Kinnula VL; Mannermaa A; Soini Y
Cancer Res; 2012 Nov; 72(21):5537-46. PubMed ID: 22964583
[TBL] [Abstract][Full Text] [Related]
14. IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10 years of age.
Ferris SP; Goode B; Joseph NM; Kline CN; Samuel D; Gupta N; Bollen A; Perry A; Mueller S; Solomon DA
Acta Neuropathol; 2016 Jul; 132(1):153-5. PubMed ID: 27161253
[No Abstract] [Full Text] [Related]
15. WT1 Clone 6F-H2 Cytoplasmic Expression Differentiates Astrocytic Tumors from Astrogliosis and Associates with Tumor Grade, Histopathology, IDH1 Status, Apoptotic and Proliferative Indices: A Tissue Microarray Study.
Abd El-Hafez A; Ismail Hany HSED
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2403-2413. PubMed ID: 32856872
[TBL] [Abstract][Full Text] [Related]
16. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
17. Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.
Ramachandran RK; Sørensen MD; Aaberg-Jessen C; Hermansen SK; Kristensen BW
PLoS One; 2017; 12(2):e0172234. PubMed ID: 28234925
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of survivin and DNA topoisomerase IIα in diffuse and anaplastic astrocytomas.
Varughese RK; Skjulsvik AJ; Torp SH
Pathol Res Pract; 2017 Apr; 213(4):339-347. PubMed ID: 28214203
[TBL] [Abstract][Full Text] [Related]
19. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome.
Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Pierscianek D; Kim YH; Mariani L; Vital A; Ohgaki H
J Neuropathol Exp Neurol; 2012 Aug; 71(8):702-7. PubMed ID: 22805772
[TBL] [Abstract][Full Text] [Related]
20. Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors.
Cai J; Chen J; Zhang W; Yang P; Zhang C; Li M; Yao K; Wang H; Li Q; Jiang C; Jiang T
Oncotarget; 2015 Jul; 6(20):18105-15. PubMed ID: 25971279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
